Active, not recruitingPhase 2NCT06188559
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
Studying Epidermal disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eisai Inc.
- Intervention
- BB-1701(drug)
- Enrollment
- 135 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
- UCLA Center for East-West Medicine, Los Angeles, California, United States
- UCSF, San Francisco, California, United States
- Yale New Haven Hospital, New Haven, Connecticut, United States
- AdventHealth Cancer Institute - Orlando, Orlando, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Fort Wayne Medical Oncology & Hematology, Fort Wayne, Indiana, United States
- Community Cancer Center South, Indianapolis, Indiana, United States
- Mission Blood and Cancer, Des Moines, Iowa, United States
- University of Michigan Hospital, Ann Arbor, Michigan, United States
- Washington University in St. Louis School of Medicine, St Louis, Missouri, United States
- NHO Revive Research Institute LLC, Lincoln, Nebraska, United States
- Nebraska Cancer Specialist, Omaha, Nebraska, United States
- Astera Cancer Care, East Brunswick, New Jersey, United States
- Summit Medical Group, Florham Park, New Jersey, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06188559 on ClinicalTrials.govOther trials for Epidermal disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07222215PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)Kristina A. Fanucci
- RECRUITINGPHASE1NCT07214662A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerGenentech, Inc.
- RECRUITINGPHASE1, PHASE2NCT07049055A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic CancerEngeneic Pty Limited
- RECRUITINGPHASE1NCT07361237A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationsTongji University
- RECRUITINGPHASE2, PHASE3NCT07100080Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07216183Epidermal Sensors for Wireless and Enhanced Amputee Skin Tracking (E-SWEAT) Part 1North Carolina State University
- RECRUITINGPHASE3NCT06982521Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerRelay Therapeutics, Inc.
- RECRUITINGPHASE2NCT06348134Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryUniversity of Chicago